Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> through Inhibition of IL-6 Signaling and EMT Reversal

Abstract

Metformin, generally considered nontoxic and remarkably inexpensive, might be used in combination with TKIs in patients with non-small cell lung cancer, harboring EGFR mutations to overcome TKI resistance and prolong survival.